Clinical trial
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid…
NCT00095836 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00095836 |
|---|---|
| Title | Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy |
| Official title | A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Cancer Institute (NCI) NIH Dana-Farber Cancer Institute Brigham and Women's Hospital AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 27 |
| Start date | Mar 1, 2003 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Nov 9, 2004 |
| Last update posted | May 31, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: